You are here

ICER

Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group

Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group

Yahoo/Reuters

Vertex Pharmaceutials

CRISPR Therapeutics

sickle cell disease

Flag link:

ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount

ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount

Fierce Pharma

Alzheimer's disease

Flag link:

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Stat

Alzheimer's disease

Flag link:

Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper

Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper

Endpoints

Inflation Reduction Act

Flag link:

On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega

On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega

Fierce Pharma

Flag link:

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Flag link:

ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab

ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab

Endpoints

multiple sclerosis

TG Therapeutics

Flag link:

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

BioSpace

Flag link:

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

Endpoints

Flag link:

Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care

Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care

Endpoints

Flag link:

ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal

ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal

Fierce Pharma

Ridgeback Biotherapeutics

Flag link:

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

Pharmaforum

Flag link:

A rarity for ICER: Cost watchdog says Covid-19 therapeutics appropriately priced in the US

A rarity for ICER: Cost watchdog says Covid-19 therapeutics appropriately priced in the US

Endpoints

Flag link:

FDA delays its decision on Bristol Myers' $13B heart drug another three months

FDA delays its decision on Bristol Myers' $13B heart drug another three months

Endpoints

Bristol Myers Squibb

Flag link:

FDA delays its decision on Bristol Myers' $13B heart drug another three months

FDA delays its decision on Bristol Myers' $13B heart drug another three months

Endpoints

Bristol Myers Squibb

obstructive hypertrophic cardiomyopathy

Flag link:

ICER: Unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past

ICER: Unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past

Endpoints

Flag link:

Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug

Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug

Fierce Pharma

Flag link:

ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits

ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits

Endpoints

Alzheimer's disease

Flag link:

Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say

Good pharma citizenship is more than tree hugging. ESG needs drug pricing input, analysts say

Fierce Pharma

corporate citizenship

Flag link:

Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?

Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?

Endpoints

Alzheimer's disease

Flag link:

Pages